News Brilique boosted by NICE’s long-term prevention recommendati... Recommendation will add to growth trajectory
News AZ's key drug Brilique fails in stroke trial Disappointment for AstraZeneca and key growth driver
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
